Short Interest in Soligenix, Inc. (NASDAQ:SNGX) Decreases By 64.9%

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 47,100 shares, a drop of 64.9% from the October 15th total of 134,300 shares. Based on an average trading volume of 135,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.1% of the shares of the company are short sold.

Institutional Investors Weigh In On Soligenix

Large investors have recently added to or reduced their stakes in the business. Stephens Inc. AR acquired a new stake in Soligenix during the third quarter worth approximately $184,000. Armistice Capital LLC bought a new position in shares of Soligenix during the second quarter worth approximately $206,000. Finally, OLD National Bancorp IN acquired a new stake in Soligenix during the 2nd quarter worth approximately $26,000. Institutional investors own 3.60% of the company’s stock.

Soligenix Price Performance

NASDAQ:SNGX traded down $0.14 on Friday, hitting $3.54. The company’s stock had a trading volume of 14,221 shares, compared to its average volume of 840,590. Soligenix has a one year low of $1.83 and a one year high of $32.00. The stock has a fifty day moving average of $3.76 and a two-hundred day moving average of $4.36.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.